Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Raymond

Showing results (501-510 of 1,063) with videos related to

Pageof 107
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 22, 2018
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challengeC M Parseghian, J M Loree, V K Morris, et al.
Journal of Inherited Metabolic Disease|January 18, 2023
Fractionated plasma N-glycan profiling of novel cohort of ATP6AP1-CDG subjects identifies phenotypic associationHana Alharbi, Earnest James Paul Daniel, Jenny Thies, et al.
Bioorganic & Medicinal Chemistry Letters|September 26, 2008
Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitorsMalcolm Anderson, David M Andrews, Andy J Barker, et al.
Journal of Medicinal Chemistry|August 13, 2013
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)Richard A Ward, Mark J Anderton, Susan Ashton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2019
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung CancerJulia K Rotow, Philippe Gui, Wei Wu, et al.
Journal of Inherited Metabolic Disease|March 18, 2021
ALG13 X-linked intellectual disability: New variants, glycosylation analysis, and expanded phenotypesHind Alsharhan, Miao He, Andrew C Edmondson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 17, 2020
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver MutationsMarcelo V Negrao, Victoria M Raymond, Richard B Lanman, et al.
Nature Communications|November 9, 2019
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activityJacqueline H L Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, et al.
Molecular Cancer Therapeutics|March 13, 2023
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination PartnersAatman S Doshi, Susan Cantin, Marylens Hernandez, et al.
Cancer Discovery|June 5, 2014
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerDarren A E Cross, Susan E Ashton, Serban Ghiorghiu, et al.
Pageof 107

Showing results (501-510 of 1,063) with videos related to

Sort By:
Pageof 107
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 22, 2018
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challengeC M Parseghian, J M Loree, V K Morris, et al.
Journal of Inherited Metabolic Disease|January 18, 2023
Fractionated plasma N-glycan profiling of novel cohort of ATP6AP1-CDG subjects identifies phenotypic associationHana Alharbi, Earnest James Paul Daniel, Jenny Thies, et al.
Bioorganic & Medicinal Chemistry Letters|September 26, 2008
Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitorsMalcolm Anderson, David M Andrews, Andy J Barker, et al.
Journal of Medicinal Chemistry|August 13, 2013
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)Richard A Ward, Mark J Anderton, Susan Ashton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2019
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung CancerJulia K Rotow, Philippe Gui, Wei Wu, et al.
Journal of Inherited Metabolic Disease|March 18, 2021
ALG13 X-linked intellectual disability: New variants, glycosylation analysis, and expanded phenotypesHind Alsharhan, Miao He, Andrew C Edmondson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 17, 2020
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver MutationsMarcelo V Negrao, Victoria M Raymond, Richard B Lanman, et al.
Nature Communications|November 9, 2019
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activityJacqueline H L Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, et al.
Molecular Cancer Therapeutics|March 13, 2023
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination PartnersAatman S Doshi, Susan Cantin, Marylens Hernandez, et al.
Cancer Discovery|June 5, 2014
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerDarren A E Cross, Susan E Ashton, Serban Ghiorghiu, et al.
Pageof 107